---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-073456"
form_type: "8-K"
ticker: "NTLA"
cik: "0001652130"
company_name: "Intellia Therapeutics, Inc."
filed_at: "2026-02-26T23:59:59+00:00"
generated_at: "2026-05-15T23:39:29.931829+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Intellia Q4 net loss $95.8M; lonvo-z Phase 3 data mid-2026; nex-z clinical hold remains for ATTR-CM

## Summary
- Q4 2025 net loss $95.8M vs $128.9M Q4 2024; cash $605.1M, expected to fund operations into H2 2027.
- Lonvo-z (HAE): HAELO Phase 3 topline data by mid-2026; BLA submission H2 2026; U.S. launch anticipated H1 2027.
- Nex-z (ATTR): MAGNITUDE-2 enrollment restart underway, completion expected H2 2026; MAGNITUDE clinical hold on ATTR-CM unresolved.
- Market research: 99% of HAE patients likely to take lonvo-z; 92% of physicians would prescribe.
- R&D expenses $88.7M (down from $116.9M); collaboration revenue $23.0M (up from $12.9M) including $9.0M from SparingVision termination.

## SEC filing metadata
- accession: 0001193125-26-073456
- form_type: 8-K
- ticker: NTLA
- cik: 0001652130
- company_name: Intellia Therapeutics, Inc.
- filed_at: 2026-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1652130/000119312526073456/0001193125-26-073456-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1652130/000119312526073456/ntla-20260226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-073456
- JSON: https://secwatch.observer/filing/0001193125-26-073456.json
- Plain text: https://secwatch.observer/filing/0001193125-26-073456.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.